Detection and comparison of EGFR mutations in matched tumor tissues, cell blocks, pleural effusions, and sera from patients with NSCLC with malignant pleural effusion, by PNA clamping and direct sequencing

Lung Cancer

Volumn 81, Issue 2, 2013, Pages 207-212

  Yeo, Chang Dong ^a   Kim, Jin Woo ^a   Kim, Kwan Hyoung ^a   Ha, Jick Hwan ^b   Rhee, Chin Kook ^b   Kim, Seung Joon ^b   Kim, Young Kyoon ^b   Park, Chan Kwon ^c   Lee, Sang Haak ^d   Park, Mi Sun ^d   Yim, Hyeon Woo ^d  

^a Uijeongbu St Mary's Hospital   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d The Catholic University of Korea   (South Korea)

Author keywords

Direct sequencing; EGFR mutation; Lung cancer; Malignant pleural effusion; Peptide nucleic acid mediated real time PCR clamping

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; PEPTIDE NUCLEIC ACID;

AGED; ARTICLE; BLOOD SAMPLING; BODY FLUID; CANCER TISSUE; CLAMP; CLINICAL ARTICLE; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GENE SEQUENCE; HUMAN; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; MALE; PLEURA EFFUSION; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

DIRECT SEQUENCING; EGFR MUTATION; LUNG CANCER; MALIGNANT PLEURAL EFFUSION; PEPTIDE NUCLEIC ACID-MEDIATED REAL-TIME PCR CLAMPING;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PEPTIDE NUCLEIC ACIDS; PLEURAL EFFUSION, MALIGNANT; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE ANALYSIS, DNA;

EID: 84879887910     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.04.023     Document Type: Article

References (24)

1. Tanner N.T., Pastis N.J., Sherman C., Simon G.R., Lewin D., Silvestri G.A. The role of molecular analyses in the era of personalized therapy for advanced NSCLC. Lung Cancer 2012, 76:131-137.
2. Pao W., Ladanyi M. Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res 2007, 13:4954-4955.
3. Pirker R., Herth F.J., Kerr K.M., Filipits M., Taron M., Gandara D., et al. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol 2010, 5:1706-1713.
4. Endo K., Konishi A., Sasaki H., Takada M., Tanaka H., Okumura M., et al. Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. Lung Cancer 2005, 50:375-384.
5. Han H.S., Lim S.N., An J.Y., Lee K.M., Choe K.H., Lee K.H., et al. Detection of EGFR mutation status in lung adenocarcinoma specimens with different proportions of tumor cells using two methods of differential sensitivity. J Thorac Oncol 2012, 7:355-364.
6. Kim H.J., Kim W.S., Shin K.C., Lee G.H., Kim M.J., Lee J.E., et al. Comparative analysis of peptide nucleic acid (PNA)-mediated real-time PCR clamping and DNA direct sequencing for EGFR mutation detection. Tuberc Respir Dis 2011, 70:21-27.
7. Lee K.Y., Kim H.J., Kim S.J., Yoo G.H., Kim W.D., Oh S.Y., et al. clamping for the detection of EGFR mutations in non-small cell lung cancer. Tuberc Respir Dis 2010, 69:271-278.
8. Antony V.B., Loddenkemper R., Astoul P., Boutin C., Goldstraw P., Hott J., et al. Management of malignant pleural effusions. Eur Respir J 2001, 18:402-419.
9. Kawahara A., Azuma K., Sumi A., Taira T., Nakashima K., Aikawa E., et al. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry. Lung Cancer 2011, 74:35-40.
10. Kimura H., Fujiwara Y., Sone T., Kunitoh H., Tamura T., Kasahara K., et al. High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients. Cancer Sci 2006, 97:642-648.
11. Liu Y., Liu B., Li X.Y., Li J.J., Qin H.F., Tang C.H., et al. A comparison of ARMS and direct sequencing for EGFR mutation analysis and tyrosine kinase inhibitors treatment prediction in body fluid samples of non-small-cell lung cancer patients. J Exp Clin Cancer Res 2011, 30:111.
12. Zhang X., Zhao Y., Wang M., Yap W.S., Chang A.Y. Detection and comparison of epidermal growth factor receptor mutations in cells and fluid of malignant pleural effusion in non-small cell lung cancer. Lung Cancer 2008, 60:175-182.
13. Kim H.J., Lee K.Y., Kim Y.C., Kim K.S., Lee S.Y., Jang T.W., et al. Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Lung Cancer 2012, 75:321-325.
14. Soh J., Toyooka S., Aoe K., Asano H., Ichihara S., Katayama H., et al. Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer. Int J Cancer 2006, 119:2353-2358.
15. Jian G., Songwen Z., Ling Z., Qinfang D., Jie Z., Liang T., et al. Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer. J Cancer Res Clin Oncol 2010, 136:1341-1347.
16. Maskell N.A., Butland R.J. BTS guidelines for the investigation of a unilateral pleural effusion in adults. Thorax 2003, 58(Suppl 2). ii8-17.
17. Miyamae Y., Shimizu K., Mitani Y., Araki T., Kawai Y., Baba M., et al. Mutation detection of epidermal growth factor receptor and KRAS genes using the smart amplification process version 2 from formalin-fixed, paraffin-embedded lung cancer tissue. J Mol Diagn 2010, 12:257-264.
18. Jeong D., Jeong Y., Lee J., Baek M., Kim Y., Lee J., et al. Rapid and sensitive detection of KRAS mutation by peptide nucleic acid-based real-time PCR clamping: a comparison with direct sequencing between fresh tissue and formalin-fixed and paraffin embedded tissue of colorectal cancer. Korean J Pathol 2011, 45:151-159.
19. Kimura H., Kasahara K., Kawaishi M., Kunitoh H., Tamura T., Holloway B., et al. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res 2006, 12:3915-3921.
20. Kim S.T., Jung H.Y., Sung J.S., Jo U.H., Tanaka T., Hagiwara K., et al. Can serum be used for analyzing the EGFR mutation status in patients with advanced non-small cell lung cancer?. Am J Clin Oncol 2012.
21. He C., Liu M., Zhou C., Zhang J., Ouyang M., Zhong N., et al. Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer. Int J Cancer 2009, 125:2393-2399.
22. Qin L., Zhong W., Zhang L., Li L.Y., Wang M.Z. Comparison of three methods for detecting epidermal growth factor receptor mutations in plasma DNA samples of Chinese patients with advanced non-small cell lung cancer. Chin Med J (Engl) 2011, 124:887-891.
23. Bai H., Mao L., Wang H.S., Zhao J., Yang L., An T.T., et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol 2009, 27:2653-2659.
24. Maheswaran S., Sequist L.V., Nagrath S., Ulkus L., Brannigan B., Collura C.V., et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008, 359:366-377.